Glenmark’s RYALTRIS FDA Approved for Kids; Neetu Yoshi Wins Rail Deal

Glenmark’s specialized RYALTRIS nasal spray just scored a major market expansion with USFDA approval for a younger demographic, while Neetu Yoshi secured a substantial Rs 17.12 crore contract from Indian Railways for critical components.

📌 What Happened?

Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals, received USFDA approval to expand the use of its RYALTRIS Nasal Spray. This extends its application for treating Seasonal Allergic Rhinitis symptoms in pediatric patients aged 6 to under 12 years.

This approval, supported by a Phase 3 study involving 446 children, means RYALTRIS is now approved in the United States for patients aged 6 years and older.

Separately, Neetu Yoshi secured a purchase order worth approximately Rs 17.12 crore from Integral Coach Factory (ICF), Chennai, a unit of Indian Railways. The order is for manufacturing and supplying various cast steel components.

Deliveries for these components will commence immediately and continue in phased shipments from October 1, 2026, to September 30, 2027.

💰 Why It Matters

For Glenmark, this USFDA expansion for RYALTRIS opens up a significant new patient demographic, potentially boosting sales and market share. It signals continued growth in specialized pharmaceutical products and successful regulatory navigation.

Neetu Yoshi’s substantial contract highlights robust demand within India’s railway infrastructure sector. This order provides strong revenue visibility for the foundry, which also operates an integrated CNC machine shop, extending well into 2027.

👀 What to Watch Next

Investors should monitor Glenmark’s future earnings reports for insights into how quickly RYALTRIS sales grow within this newly approved pediatric segment.

Keep an eye on Neetu Yoshi for potential further contracts from Indian Railways as the country continues its aggressive infrastructure development plans.